Moderna and Pfizer Begin Late-Stage Coronavirus Vaccine Trials

The first large study of the safety and effectiveness of a coronavirus vaccine in the United States began on Monday morning, according to the National Institutes of Health and the biotech company Moderna, which collaborated to develop the vaccine.

Six COVID-19 vaccine candidates in phase-3 trials, 3 from China

The vaccines will be put into the general population for the first time in phase 3, after previous trials have focused on safety, immunogenicity and immune response in a small number of humans, said the WHO official. The phase-3 trial will test whether the vaccines can "protect large numbers of people over a prolonged period of time."

Moderna coronavirus vaccine shows promising results in early clinical trial

An experimental coronavirus vaccine developed by Moderna provoked an immune response without major side effects in an early-stage clinical trial, scientists reported Tuesday in the New England Journal of Medicine.The vaccine is the first developed by a U.S. company to publish clinical trial results.

Why have 14,000 people volunteered to be infected with coronavirus?

Imagine being told to inhale a nasal spray full of coronavirus. More than 14,000 people in the U.S. and elsewhere are putting their names forward to do so. They are volunteering for what's called a "human challenge trial," an ethically controversial way to test vaccines that would deliberately infect people with a virus that has killed over 270,000 people worldwide and has no cure.

Oxford professor: Possible coronavirus vaccine could show efficacy by June

Sir John Bell, the Regius Professor of Medicine at Oxford University, said Sunday that researchers at the university working on a potential vaccine for the coronavirus would likely have an idea of its efficacy by June. Bell called the chances of success in developing a vaccine “pretty good,” adding “we are gradually reeling it in, bit by bit and as every day goes by, the likelihood of success goes up.”

Coronavirus: First patients injected in UK vaccine trial

Two volunteers were injected, the first of more than 800 people recruited for the study. Half will receive the Covid-19 vaccine, and half a control vaccine which protects against meningitis but not coronavirus. The design of the trial means volunteers will not know which vaccine they are getting, though doctors will.